Genexine, a Korean biopharmaceutical company, has merged with EPD Biotherapeutics, specializing in targeted protein degradation (TPD) technology. This merger aims to bolster Genexine’s research capabilities and drug pipeline.
EPD Bio’s bioPROTAC platform, EPDegTM, offers several advantages over traditional small molecule-based PROTAC technology. It utilizes mRNA-LNP delivery to overcome tissue-specific limitations of E3 ligase expression, enabling the development of a diverse pipeline of TPDs for various undruggable targets.
The merger brings onboard Dr. Jaehyun Choi, EPD Bio’s founder and CEO, as Genexine’s representative director for R&D. This strengthens Genexine’s expertise in TPD technology and aligns with its goal of developing innovative drugs to address unmet medical needs.
Genexine’s focus on immunotherapeutics and next-generation biologics complements EPD Bio’s TPD platform. This combination allows Genexine to pursue the development of novel therapies for a range of diseases, including cancer, growth hormone deficiency, and CKD-induced anemia.
The merger is expected to expedite Genexine’s mission of discovering and commercializing effective biologics. With EPD Bio’s expertise and clinical and CMC development capabilities, Genexine aims to lead the global market in innovative drug development.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
